Ribomic, Inc. (JP:4591) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
RIBOMIC Inc., a biopharmaceutical firm, has completed enrollment for its early Phase II study of umedaptanib pegol, a potential treatment for Achondroplasia in children. The study, which involves dosing cohorts at varying levels, aims to assess the efficacy and safety of the drug, with no safety concerns reported to date. The company remains on track with its full-year earnings guidance previously announced.
For further insights into JP:4591 stock, check out TipRanks’ Stock Analysis page.